Assay of TMPRSS2:ERG and PCA in Canary PASS
No involved investigator sites defined.
The identification of biomarkers that, at the time of diagnosis, associate with the presence of, or progression to, aggressive prostate cancer will transform the clinical management of this malignancy. If patients and their physicians have reliable and valid tools for estimating the risk of disease-specific morbidity, then more patients might opt for and adhere to active surveillance regimens, and consequently reduce overtreatment and the attendant substantial costs and harms. Also, a marker or marker panel with high accuracy for progression on active surveillance will identify those men who could be placed on less intensive surveillance protocols with fewer repeated prostate biopsies, reducing the risks and costs of invasive procedures. The study presented here is a step toward validating such biomarkers.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.